Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let us wait until another filtration company makes a big $plash with the FDA or perhaps big pharma or better yet both!
Great management here, maybe the best?
I like Spectral Medical of Canada. I have for a long time. I like companies that those with the most intimet of intel like...especially if they like it A LOT.
AEMD seems pretty good too. I like their management.
Shameless plug, not me, but rather EDTXF mentioned today in the Baxter presentation as an acute therapy partner. It only trades on the PINKS as a means of hiding itself from the market. It more commonly trades in Canada on the Toronto stock exchange as T.EDT. I love it and Baxter apppears intetrested as well. Things that make you go HMMMM?
PS...massive insider ownership and involvement with Toray of Japan, Infomed of Switzwerland and Fresenius of Germany just to name drop a few.
I smell a change of forum direction and purpose. I have yet to see this talked down the way it currently is. My gut tells me that the entire filtration group is set to become of interest to a large number of people. If just one little company that is uber advanced makes head way with the FDA, then all the other players will join the party. I might suggest that other companies are preparing for the upcoming interest. Why would anyone place a large of amount of money into this one anyway? I have never seen any significant proof of efficacy. In layman terms, data from a proper RCT arrangement has never been attached to anything I have seen here. By all means, if you have such proof or data to share please do. It can only be of help to all shareholders. Wishing you all good luck and remember you are all winners in your own special way!
Given our timelines, I think we need a rabbit so to speak. We need a runner or a trend setter. I'd like to see a company show some real positive sepsis results all the back of a theragnostic approach with the use of precision medicines. I sure hope it is us as I know some diagnostic companies are working the cytokine angle in a big way. Hearing more and more about covid leading to sepsis. In some circles it is believed that endotoxin is present in about 75% of those with severe covid. It sure does scream for our sorb XL product. I've heard it is amazing! Even if it is still pre-clinical. Great luck to each and every handle that tells the story here. You are all winners!
Gallon of petrol against the price of a cyto share. Jeezum Crow! Never thought I would see that ugly ratio. My screen shows a low today of $1.89. Is that correct or was that some silly pre-market number on 10 shares? Thanks in advance fellow CTSO followers. Sure glad I only have a few left now. Does anyone think the tanking share price is related to German salesforce issues like it was years back when it was in the $15 zone? Appreciate the thoughts of the heavy thinkers installed here.
I'm thinking Hemo must be real close. Not to mention the next Gen XL filter. Just wait when some other company achieves astounding success with endotoxin and the XL filter is held up like a Lombardi trophy. Yeah, I suppose those promises of $80 per share made by the fellas here could have been a little excessive. Let's go with that over the nefarious commentary shall we gang. I lost track of that Canadien filter group, wouldn't surprise me a bit if Tellum took his near 5 million rewards and headed back to the lab...one never really does know unless of course they have close friends that do.
You people sound like novice investors. I believe you people to be the sound group that were claiming $60 and $80 per share when the stock was running up towards $15 a few years back. The FDA trials they were running back then ended up being futile and are no longer active. They were called RE FRESH and then REFRESH 2. Until we achieve FDA approval with the ability to advertise hard data, this will remain as it is. I'm never comfortable seeing a small cap bio play being run before data. I'm glad I followed that rule here. I wish you all good luck and remind you that management is important, however without a product able to show FDA backed efficacy, really you are trading on hype. Such hype was easily detected in the old program run on this very forum along with other forums run by the same group.
Happy weekend to all CTSO longs!
Shame on you for being so negative. You remind me of the people on the Canadian forums that spend all their time trashing Canadian filtration companies while they push towards their 5th FDA approval. Sure, I only have a few left but I am fully behind the company mostly from a humanitarian perspective as I believe filtration and in particular endotoxin removal is set to change septic strategies as it pertains to the critically ill. Does anybody know how many presentations we are doing at the current AKI show in San Diego? It is a rather large and important show. The Canadian filter companmy is doing like 4 or 5 sessions most of which are being led by Dr. Kellum from Pittsburgh. I would expect CTSO is doing at least as many however I have yet to see their scheduled appearances. Let's keep this on the up and up guys. We are all here to share and support our investment...like they say, "for better or for worse"!
Hemodefend? Anyone know how the trial for Hemodefend is progressing? I am certain they talked about starting this trial about 2 or maybe 3 years ago. Is it FDA registered and at what stage are we? This product is designed for battlefield conflict. Given we are dealing with potentially the largest conflict since the 2nd world war, I see this Hemodefend angle as a real positive for CTSO. Anyone with intell on this please chime in. Good luck to all longs !!
The promotion of medical product or in this case a medical device used in a critical care setting is not something you talk either about or up. These products require proven efficacy by way of properly structured FDA RCT trials. Until such time that data like this exists, talking or promoting will do little to move company value. Ask Fresenius how important it is for our CEO to promote our company. Stay patient as it is very likely that at some point we will find the sweet spot for our device and be able to tout efficacy. Until such time, your calls for CEO promotion seem rather silly and make you look a tad like a novice investor. Please don't take offence, but rather revisit your commentary. Have a wonderful day.
Great Andy! I am delighted to see CTSO back in the sepsis game! I thought they left this arena in search of riches in the removal of blood thinners in advance of emergency cardiac surgery. Glad to once more be proven wrong. I have 25 shares left and will likely be gripping them tightly based on this new and most important development. Thanks Andy, you are quite definitely the best. Somewhere in that imaginary virtual blue sky Berthablowfish is smiling down on you Andy!
Shutdown of the RE-Fresh FDA trial could be a blessing in disguise everybody. I am kind of looking forward to the new trial ramping up. The execs sound excited about it. I don't really know enough to comment about the chances of success. I would like to suggest we all band together and do as below suggests. Please NO more negativity from the sore losers here on the IHUB:
Kumbaya fellow CTSO holders! Come on ladies and gents we are only doing further damage to our position with this terrible in-fighting and lack of common belief in the beads. I am unable to either say or spell the newest condition we are seeking FDA approval for but do hope for a FDA breakthrough as we are long overdue for some solid scientific backing that leads to true value building for the company. I have maintained that it is in fact the lack of hard FDA data and real efficacy numbers that we are lacking. True enough the covid trial in Germany that was shutdown for reasons unknown to myself did start the most recent slide in my opinion. I also believe that losing our star KOL and long time special advisor Dr. J Kellum to a Canadian competitor also allowed for pause and reflection as to just how, where and when we might gain the much needed traction we now appear so deperate to obtain. I really have next to nothing left but do feel the pain of long time holders especially if they bought with the dreams of $40, $50, $60 and even $80 that were promised here in the past. I have to believe those that promised were just wrong and not out to mislead or harm those too naive to know otherwise. I maintain my belief in people and don't wish to consider them cruel or unkind, that would destroy my belief that most people are good and honest. Let's band together and stay positive shall we? Life is too short to attack one another in this fashion. Kumbaya! and wishing the best for CTSO and all it's loyal shareholders
The end of the RE-FRESH era! I will say that I was a little shaken this morning to learn the RE-FRESH 2 FDA process has been shutdown. Loyal CTSO longs know all about RE-FRESH and now version 2 of this important FDA process that links us to assisting patients during cardiac in attempting to avoid AKI or acute kidney injury. I am disappointed in this decision but do understand the decision to change course and now chase what appears to be our best shot at obtaining the elusive nod from the FDA. Is it just me or does it feel like we have changed direction and switched our focus quite a few times over the years? Sepsis, AKI and now removing blood-thiners appears our best shot. I wish shareholders and the company well. Let us all support and be supportive of the efforts and thank management for an excellent letter today providing clarity and continued revenue to drive the newest focus and push for FDA approval. Good luck CTSO longs!!!!
Kumbaya fellow CTSO holders! Come on ladies and gents we are only doing further damage to our position with this terrible in-fighting and lack of common belief in the beads. I am unable to either say or spell the newest condition we are seeking FDA approval for but do hope for a FDA breakthrough as we are long overdue for some solid scientific backing that leads to true value building for the company. I have maintained that it is in fact the lack of hard FDA data and real efficacy numbers that we are lacking. True enough the covid trial in Germany that was shutdown for reasons unknown to myself did start the most recent slide in my opinion. I also believe that losing our star KOL and long time special advisor Dr. J Kellum to a Canadian competitor also allowed for pause and reflection as to just how, where and when we might gain the much needed traction we now appear so deperate to obtain. I really have next to nothing left but do feel the pain of long time holders especially if they bought with the dreams of $40, $50, $60 and even $80 that were promised here in the past. I have to believe those that promised were just wrong and not out to mislead or harm those too naive to know otherwise. I maintain my belief in people and don't wish to consider them cruel or unkind, that would destroy my belief that most people are good and honest. Let's band together and stay positive shall we? Life is too short to attack one another in this fashion. Kumbaya! and wishing the best for CTSO and all it's loyal shareholders.
Twas never in the high $20's. It reached $15 and change prior to the German Salesforce crisis. I think you better look at your chart. I am surporised we put in a new 52 wk low that is almost 10% below the previous mark. Anyone know who is selling?
Blame belongs where? I would ask Fresenius why they bailed on Europe. Was it because they didn't like Phil, or because they didn't have any hard RCT data to back the efficacy of the filter. This would go a long way in determining just what the problem is. This is my opinion, what is others?
Another 52 week Low! What the hay is going on with this company! I recently spoke to a real indusrty leader and will not mention his name as he was open and candid with me in discussing my hard times with CTSO. His suggestion was that the entire hemo filter group of companies would be lifted if a major pharma were to join forces with one of them and get behind the concept of blood filtration in both the area of critical illness and of course covid ninenteen. He seemed to mention this idea of "precision medicine" a few times. He explained that like cancer care we needed to have guidance to specialize treatment for the crtically ill. He would not share his thoughts on which company was furthest down the road with a major however with that said he asked me if I kept track of where the real KOL's are spending their time. I got the hint and just bought a little more of the company I believe he was pointing me to. I won't mention the company as it would allow for my message to get deleted. Would not want that as I only get one message per day as per my ban. OH well, you good people will need to figure it out. You can guess if you want, it might be a fun exercise!!
Another 52 week low! This high end data flow from Andy is wonderful and yet it is doing nothing but shaving value off the misunderstood gem! Where are all the forum friends that predicted $40, $50 and up to $80 for this 20 year old device company? I should have learned my lesson and stayed away from forums that were high on hype and limited on randomized control data. Is this number 3,4 or 5 when it comes to our FDA trial attempt? I hope this is the one that makes all the true longs the kind of money the true forum friends once promised. Hoping hard!!
Another 52 week low! As a loyal investor in this company, I want answers! Not the answers that the medical community wants but rather answers around the share price! What in the beejeepers is going on with this group!!?? I think we need some hard data to reverse the direction of the stock. I'm just hoping that the current path to the holy grail that is FDA approval is one we can navigate. So far our trial attempts have not really given us much hard data to hang our hat on. Good luck longs, I hope 2022 or 2023 0r maybe 2024 with data finalization is our year or years!!
BINGO, what is being removed? Nice release this morning around the appointment of a cardiac doc to head things up. Can someone explain why we didn't appoint a US doc instead of a German one? If our future is all about ultimately getting the almighty FDA stamp of approval, should we not have a US doc act in this role? Just my thoughts, what might yours be?
Management should be left alone! In my opinion they've done a wonderful job of building shareholder value and more importantly growing revenue. The real problem is the lack of RCT efficacy data. I have always maintained it is the biggest problem here. Hoping this new trial turns out to be the right fit for the product and subsequently shareholders. Blaming management is kind of juvenile and in many ways sounds like an excuse. If people keep doing this is gives the story itself more hope. The blood runs through the filter, the management can only take to the FDA the product in hand. Let us see where the new endeavor takes us with the FDA. Best of luck to all shareholders and great job from management given our lack of RCT data to really get this product moving with big pharma and distribution. Just my 2 cents and looking forward to data from the new trial!
Promotional strategy for AYTU. Did they buy a SELL from Zacks?
I sure hope they did. I woul load up like there is no tomorrow!
Leave management alone! This product needs some proof that it works in the form of a proper RCT. I've yet to see any compelli any data and this is like;ly why we don't have Fresenius as our EU partner any more. Stop making negative comments about the management team, they are doing all they can without the most important proof of efficacy from a proper phase 3 RCT. This just my opinion however I see it as a very real problem. Still holding on to a few however a very few as I have lost faith in our ability to be a game changer. Actually kind of sad and sure do miss the heavy pumping and chatter about $80 share prices. I sure hope that stuff was real and not some slimy online project.
Sadly, we will require proof of the miracle. Cherry picking individual cases that may or may not be related to the magical beads is not going to pass the smell test for wise investors or of course big pharma. This has been the opinion of smart people I converse with. So far they have been right on the money.
FYI Andy, as much as we appreciate you posting selected case studies, from a scientific point of view they are worthless. What is required to validate science is something called a RCT, short form for randomized control trial. Unfortuneately our experience with the toughest test to prove up our science has been rather disappointing. Just for chits and giggles I went over to read Texhxen's newest handle on the stocktwits site, not impressed. I do wish the people in charge of these on-line promotional attempts would stop blaming management, although I know it is done intentionally. Management can be changed but a 20 year old medical device with very, very limited data from RCTs proving anything specific is a problem. Good luck on this newest endeavor to find the right condition to match the sorbs filtration process. I wish all shareholders and of course the sorb team the very best of luck in the upcoming trial, whatever the name is now. Cut the blaming management though, it is very tired and very obviously a scapegoat to cover the lack of proven data. I find best in class devices start on the same path or target therapy group and stick with it. In our case here, the condition or target group seems to change rather frequently.
Good luck to all participants and good luck in the newest FDA venture
Follow the expert with Kellum. Recently he was placed in the top flight of global critical docs at a key Sepsis Alliance meeting. I find that ignorance when investing can be a costly error. Kellum's decision to take on a dual function role as CMO for the Canadian filter company should be recognized as a potential signal to would be investor types. Please, don't misunderstand me, I consider myself an internet pal with Texchen like most do, what a brilliant mind, and his picture leaves little to be desired. For me though, it is a professional of Kellum's class that gets my motor running from an investor point of view. Why would a global key opinion leader of his ilk leave all advisory roles and take a 2 year leave to join a Canadian filter company if in fact they did not have the goods? Upon further analysis they have several FDA achievments and of course a phase 4 FDA confirmatory trial well under way. From a CTSO standpoint endotoxin removal is quite large as our XL filter is said to make stand alone endotoxin filters obsolete and therefore the Canadian company's advancement only stands to be a huge benefit to us in this 20 billion dollar market. I'm once again excited and find the comment on 'pulling hard' to be both ignorant and extremely telling. Embrace advancement, embrace the KOL's and most of all embrace one another as we journey into tomorrow with knowledge we gain today. GLTA!!
I am pulling hard for Canadian filter co. and Dr. John Kellum's attempts to guide this relative unknown company.
Does anyone know the name of the company in Canada with 5 FDA approvals to it's name and a 6th in the stage 4 confirmatory process? Maybe we can learn from them? I have called for a companion diagnostic for over 5 years and was only laughed at and ridiculed. Now, one of the the planet's top sepsis or critical care docs is touting the Canadian company's EEA device as the difference make in a specific and rather large segment of the sepsis market. I thought we owned the sepsis market and called for a large piece of the 20 BILLION market opportunity. I get more confused by the day! Let us discuss and learn from our experts and their choices shall we?
Good discussion guys but this Pearsby thing sounds both juvenile and contrived. Reminds me of the German salesforce fiasco.
I'm not too sure but I will play Pearsby for purposes of your game.
The ONLY filter company with any FDA approval is the one up in Canada. Their name escapes me at the moment as I claim to be a senior like most of the characters here.
The one up in Canada has a FDA approval for their sepsis diagnostic, a FDA approval for their dialysis & filter delivery pump, a FDA approval for their home dialysis unit and a tidy arrangement with Baxter Medical. I forget the name of the company although I am certain of the approvals. I don't think the market is too impressed though they are value less than 25% of Cyto so we still know who the Big Kahuna is don't we?
Long the Sorb! love to see them try the companion diagnostic idea to prove up what we do, I think it would make a big difference. Just thinking out loud !!
Sorry guys, I can't resond until tomorrow. I once used the name of that Canadian company with all those approvals and they banned me from multiple messages, i only get 1 per day. Be patient though if you have a question, I will answer tomorrow for a hamburger today.
Anyone talk to Cesare lately? Are we still or have we ever done business with Baxter? I know the Canadian filter company does business with them now. Baxter gave them 5 million for rights to sell the product as an upfront. The Canadian filter company is well into their phase 4 confirmatory trial with the FDA and are actually seeing their filter used on 2 of every 3 critically ill patients. Perhaps the mosting exciting part of this is the fact the primary endpoint for the trial is 28 day mortality. People have been saying that 28 day mortality is the holy grail for sepsis and could likely never get done in a RCT. Perhaps the use of a companion diagnostic is the solution and perhaps this is why Dr.J Kellum of Pittsburgh moved to a full time role with the Canadian company. Dr. Kellum used to advise for CTSO however I don't see him listed anymore. Just curious on everyone's thoughts here, is the Canadian company making covert advances that seem to elude even the smartest investors with CTSO? Anyway, here is Cesare's words from a few years back, I had saved it in my CTSO folder..
caesare74 Wednesday, 11/01/17 06:06:00 PM
Re: mikesmith999945 post# 10145 0
Post #
10148
of 26835
correcet Mike. I forgot to mention Baxter. As you say, something very positiv is definitely on the radar
The quarterback is easy to replace, bring in the 2nd stringer or even the rookie 3rd option holding the clipboard. My concern would be the ball itself, is it regulation?, is it inflated to the right level and even more importantly is our ball going to be replaced by that ball from up north that is used on the 110 yard field? Sometimes this game feels as though it is being extended simply by abusing and dumping on management. I've yet to see anyone proof that our "ball" works as advertised. It could be that is why Fresenius left us holding the ball in the European theartre. Hope I am wrong of course, I still hold 50 big ones!
I 100% agree with bio48. Stop the silly talk of management being the problem. How about the actual product? How is it really performing? Based the FDA trial experience to this point, we do not really know do we?
Blaming management is a masking mechanism. The product itself needs some FDA data to back it's efficacy. I don't believe the CE mark required anything more than a safety check. I believe that the constant attacks on management deflect the fact that there is very little proof as to exactly how well this filter works. Fresenius were involved in Europe years back but left the relationship. Supposedly they are involved in Mexico or something. What are the sales numbers through Fresenius. This would be very telling. The fact that a companion diagnostic is not available to confirm what is said to be happening allows for a continuation of speculation. I'm looking to sell the last few I have and move on.
Blaming management is a masking mechanism. The product itself needs some FDA data to back it's efficacy. I don't believe the CE mark required anything more than a safety check. I believe that the constant attacks on management deflect the fact that there is very little proof as to exactly how well this filter works. Fresenius were involved in Europe years back but left the relationship. Supposedly they are involved in Mexico or something. What are the sales numbers through Fresenius. This would be very telling. The fact that a companion diagnostic is not available to confirm what is said to be happening allows for a continuation of speculation. I'm looking to sell the last few I have and move on.
What happened to the sepsis market? We are now down to a 1 billion opportunity? I invested here because the company used to promote a 20 billion market opportunity. How many different conditions are we going to attempt to treat? Please don't mention hemodefend anymore. This product has been on their bench for like 15 years. I spoke to an inside rep when the German covid trial was stopped due to an obvious lack of efficacy and they scoffed at the idea of hemodefend being ready for a trial anytime soon. Yesterday's news was really nothing new. The biggest run we have had here was on the back of big promises for revenue only to be disappointed by some German salesforce problem. That run took us up over $15 before the news of German problems crashed us to like $4. I am publically apologizing to Dr. Kevin as he warned me about this company. In his words, "no hard FDA data on the device, no major pharma involvement" I guess this is why Fresenius left us at the European alter some 5 years ago. Good luck to everyone here and the stories of 80 and 100 per share pricing will no longer be thrown out on the various message boards.
Wonder product or wondering about data? I for one am sick and tired of people dumping on management. Given the lack of hard data to support efficacy I feel like management should get an A+. At what point do we settle on a particular condition and achieve success so that major pharma take an interest? I don't see a press release on this most recent setback so let's wait for the official word on what is really going on. I am a little concerned about the widespread notion from the message board crowd that the product is revolutionary and the management not so wonderful. It is time to see some FDA backed proof that this product is providing meaningful benefit. I should have listened to Dr. Kevin years ago when he warned me about hollow internet pumping on biotech stocks. Very disappointed and waiting for official word from company.
Love it! Big pharma usually wants data though. I think we'll be in an even better position once the data starts rolling out from the Hemodefend trial. It has to be close now as I've been hearing Hemodefend for close to 20 years. Does anyone know where we stand in relation to a data pack on this most important component of our pipeline? Maybe AZ could have Andy55 or Techxen send them an email detailing the efficacy around our most advanced offerings? Everyone here keeps saying they love the technology and blame it all on management. Let's send AZ or another big pharma a sampling of what we know to be true! I'm all in for assisting where I can, though it is limited as I have not seen a great deal of the hard data others apparently have! GO CTSO GO!!! BTW Techxen, I don't appreciate the tone from you, I've reached out and received no response! You're not the fun-loving CTSO supporter you once were, you've changed man. I still hold fond memories of the daily efforts you've put into this project. You have a certain Canadian way about you and I for one appreciate it. Be good Miren.
Just to keep things straight. I can only post once per day despite my prestigious role as a moderator. Could you elaborate on the GFY comment? Does it mean going far you'll see in relation to the advancement of the Hemodefend trial? Maybe Miren can turn on and answer this one?
People I talk to are curious on Kellum going to EDTXF. Given his long time affiliation with CTSO and steadfast support of the beads over the years, you have to wonder if questions are arising with our lagging efforts to advance with the FDA and Spectral's significant advancements and more importantly enormous insider and institutional ownership. Let's call it as we it CTSO supporters, these guys have like 200 million shares and trade a fraction of what we do! I remain steadfast and loyal to the beads and their ability to filter with size as a differentiating factor however the market often looks to where KOL's decide to hang their hat. Claudio Ronco is another KOL that has spoken recently of the importance to prove out what you say you are filtering. using the recent set back in Germany as an example, we must ask ourselves how important it is have an efficient diagnostic test to quickly measure the results of your claim and perhaps more importantly not impact levels of other meds and even good cytokines while the patient is under filtration. I'm not a doctor but do believe the theragnostic solution will rule the day and right now EDTXF has 2/3's of their 3 part solution fully FDA approved with the third in an OPEN-label FDA phase 3b confirmatory trial where the proposed PXM device is used twice for every 3 patients. I must admit their rope a dope strategy has left me holding only a fraction of what I wish I had but I refuse to let go of the bead dream until the piper plays his final tune. Anyone here have any thoughts on what the heck this quiet group from Canada is doing and why the Japanese invention has been used safely and effectively on over 300 000 patients since the early 2000's? I'd like to hear more and understand why they are trading on the pinksheets and mostly being shorted. Is there something going on hear that constitutes more than meets the eye? Serious replies only and nice to see us up today in a late day push at the close. Long and strong the beads and special thanks to Andy for bringing us these very cool case studies every week like clockwork. Somebody with a yahoo account please run this by Techxen, he is really above all when it comes to knowledge, maybe even more than the docs just because of his relentless push for knowledge and we hope the truth!
Better look up Pittsburgh based "Alter-cyte" and then proceed to see just who controls the company and who is listed as a shareholder. You might learn a thing or two. Education can't be under-rated my fellow CTSO friend!
Also Biomad, what the heck were you suggesting with this rather ominous post of yours? A little concerning given the recent German experience, please clarify your thoughts and suggestions.
biomed64 Tuesday, 03/24/20 04:10:45 PM
Re: SABAI post# 20443 0
Post #
20446
of 26409
Several trucks carrying coffins fully loaded were seen in Istanbul today...Do we have sales presence there I wonder.
Two filtration companies have made serious advancement with the FDA. AEMD with their two FDA breakthrough designations and a very quiet little company based out of Toronto called Spectral Medical. It barely trades on the OTC and not too much more in Toronto as T.EDT. They are in a phase 4 confirmatory trial for Sepsis with 28 day mortality as the endpoint and massive inside ownership as the model. Good luck to both these science sultans!
FWIW ...the FDA is formulating near half of EDTXF's final data for the confirmatory trial using data from the phase 3 that was originally billed as a "FAILURE". Spectral was also granted the ability to use a 2 to 1 ratio in favor of their product in the confirmatory trial. Pay close attention to anonymous types wearing camo and trading where they can't be taken seriously.
I'm not too worried about the new player. I think the beads unique quality to remove based on size sets us apart. The only real advancers in the space would be AEMD and EDTXF. Both, and in particular EDTXF have made the most FDA advancement. EDTXF is closing in on approval as they are running their phase 3B confirmatory trial at now 13 US sites. The addition of Dr. John Kellum as EDTXF's CMO is paying early dividends as he has just secured the Cleveland Clinic and U of Michigan as additional phase 3B sites. Important to remember EDTXF is going the distance with 28 day mortality as the primary endpoint and the FDA is allowing a 2 to 1 ratio of use in FAVOR of the EDTXF solution. I have bought more of this stock since Kellum set up shop with the Canadian firm. I still love he beads and maintain a small position due to their unique ability to separate by size. The beads are very likely the cutting edge when it comes to filtration. ALL just my humble thoughts!!!!!!!! EDTXF trades very little and is HEAVILY insider owned, perhaps the most tightly owned 244 million shares I have ever witnessed...does this mean anything?? hard to know?